Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1Amyloid Neuropathies, Familial 1

Interventions

pembrolizumab 223Carboplatin 218Cisplatin 205Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 114Dexamethasone 102Pemetrexed 101Cyclophosphamide 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 91Fluorouracil 87Bevacizumab 83Nivolumab 74Leucovorin 72Rituximab 70Vincristine 67durvalumab 66Lenalidomide 63Etoposide 62atezolizumab 61Radiation 61Irinotecan 60130-nm albumin-bound paclitaxel 57Prednisone 56Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene × 1 year × Clear all
NCT05184088 2026-06-02

CArdiag

Lantheus Biosciences Ltd.

Phase 3 Completed
244 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡